<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Breast <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are rare and consensus about their treatment is lacking </plain></SENT>
<SENT sid="1" pm="."><plain>A population-based study of 38 breast <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, registered in the databases of two Comprehensive Dutch <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Centers from 1981 to 1999, was performed </plain></SENT>
<SENT sid="2" pm="."><plain>The median age of <z:hpo ids='HP_0000001'>all</z:hpo> female patients was 65 years (20-92): 25 patients had localized and 13 patients had disseminated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The most common type was diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), which accounted for 17 of the localized and 4 of the disseminated cases </plain></SENT>
<SENT sid="4" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), three being disseminated, was found in four patients </plain></SENT>
<SENT sid="5" pm="."><plain>There were six extranodal marginal zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (ENMZL), three being localized </plain></SENT>
<SENT sid="6" pm="."><plain>Seven <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> showed additional histological features of mucosa-associated lymphoid tissue (MALT) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Localized aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> treated with surgery and/or radiation therapy had relapse rates of 100% and 67%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi>, hydroxydaunomycin, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CHOP)-like chemotherapy with or without local irradiation led to 17% relapses in patients with localized aggressive <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Median follow-up time was 32 months (0.6-218); 37% of the patients relapsed and 24% had progressive disease </plain></SENT>
<SENT sid="10" pm="."><plain>Response to salvage regimens, given to 91% of the patients with <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e>, was poor </plain></SENT>
<SENT sid="11" pm="."><plain>The 2-year overall survival rate was 63%, 72% for patients with <z:e sem="disease" ids="C0277565" disease_type="Disease or Syndrome" abbrv="">localized disease</z:e>, and 46% for patients with disseminated <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The majority of breast <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are localized aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> that should be treated initially with CHOP-like chemotherapy with or without irradiation </plain></SENT>
<SENT sid="13" pm="."><plain>The initial choice of treatment is very important because response to salvage regimens is poor </plain></SENT>
</text></document>